Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.

作者: Samuele Maramai , Sandra Gemma , Simone Brogi , Giuseppe Campiani , Stefania Butini

DOI: 10.3389/FNINS.2016.00451

关键词:

摘要: D3 receptors represent a major focus of current drug design and development therapeutics for dopamine-related pathological states. Their close homology with the D2 receptor subtype makes selective antagonists challenging task. In this review, we explore relevance therapeutic utility or partial agonists endowed multireceptor affinity profile in field central nervous system disorders such as schizophrenia abuse. fact, peculiar distribution low brain abundance make them valuable target drugs devoid motor side effects classically elicited by antagonists. Recent research efforts were devoted to conception chemical templates possibly multi-target profile, especially regards other G-protein-coupled (GPCRs). A comprehensive overview recent literature is herein provided. particular, evolution has been tracked, according growing advancements both structural information refinement key pharmacophoric elements. The receptor/multireceptor functional profiles examined compounds covered, together their most significant pharmacological applications.

参考文章(93)
Christian A. Heidbreder, Amy H. Newman, Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Annals of the New York Academy of Sciences. ,vol. 1187, pp. 4- 34 ,(2010) , 10.1111/J.1749-6632.2009.05149.X
Claudia Rangel-Barajas, Israel Coronel, Benjamín Florán, None, Dopamine Receptors and Neurodegeneration Aging and Disease. ,vol. 6, pp. 349- 368 ,(2015) , 10.14336/AD.2015.0330
Julie K. Staley, Deborah C. Mash, Adaptive Increase in D3 Dopamine Receptors in the Brain Reward Circuits of Human Cocaine Fatalities The Journal of Neuroscience. ,vol. 16, pp. 6100- 6106 ,(1996) , 10.1523/JNEUROSCI.16-19-06100.1996
CRISTINA MISSALE, S. RUSSEL NASH, SUSAN W. ROBINSON, MOHAMED JABER, MARC G. CARON, Dopamine Receptors: From Structure to Function Physiological Reviews. ,vol. 78, pp. 189- 225 ,(1998) , 10.1152/PHYSREV.1998.78.1.189
Anne Dekeyne, Gilbert Lavielle, Jean-Michel Rivet, Mauricette Brocco, Mark J. Millan, Thierry Dubuffet, S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. Journal of Pharmacology and Experimental Therapeutics. ,vol. 293, pp. 1063- 1073 ,(2000)
Zheng-Xiong Xi, Jeremy Gilbert, Arlene C. Campos, Nicole Kline, Charles R. Ashby, Jim J. Hagan, Christian A. Heidbreder, Eliot L. Gardner, Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology. ,vol. 176, pp. 57- 65 ,(2004) , 10.1007/S00213-004-1858-Y
Amy Hauck Newman, Peter Grundt, Michael A Nader, None, Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. Journal of Medicinal Chemistry. ,vol. 48, pp. 3663- 3679 ,(2005) , 10.1021/JM040190E
Laura Bettinetti, Karin Schlotter, Harald Hübner, Peter Gmeiner, Interactive SAR Studies: Rational Discovery of Super-Potent and Highly Selective Dopamine D3 Receptor Antagonists and Partial Agonists Journal of Medicinal Chemistry. ,vol. 45, pp. 4594- 4597 ,(2002) , 10.1021/JM025558R
Amy Hauck Newman, Peter Grundt, George Cyriac, Jeffrey R Deschamps, Michelle Taylor, Rakesh Kumar, David Ho, Robert R Luedtke, None, N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. Journal of Medicinal Chemistry. ,vol. 52, pp. 2559- 2570 ,(2009) , 10.1021/JM900095Y
Erwan Bézard, Sandrine Ferry, Ulrich Mach, Holger Stark, Ludovic Leriche, Thomas Boraud, Christian Gross, Pierre Sokoloff, Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Medicine. ,vol. 9, pp. 762- 767 ,(2003) , 10.1038/NM875